WO2001070683A3 - 3-substituted-4-pyrimidone derivatives - Google Patents

3-substituted-4-pyrimidone derivatives Download PDF

Info

Publication number
WO2001070683A3
WO2001070683A3 PCT/JP2001/002344 JP0102344W WO0170683A3 WO 2001070683 A3 WO2001070683 A3 WO 2001070683A3 JP 0102344 W JP0102344 W JP 0102344W WO 0170683 A3 WO0170683 A3 WO 0170683A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
pyrimidone derivatives
alkyl group
group
hyperactivity
Prior art date
Application number
PCT/JP2001/002344
Other languages
French (fr)
Other versions
WO2001070683A2 (en
Inventor
Ryoichi Ando
Fumiaki Uehara
Ken-Ichi Saito
Original Assignee
Mitsubishi Tokyo Pharm Inc
Sanofi Synthelabo
Ryoichi Ando
Fumiaki Uehara
Saito Ken Ichi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tokyo Pharm Inc, Sanofi Synthelabo, Ryoichi Ando, Fumiaki Uehara, Saito Ken Ichi filed Critical Mitsubishi Tokyo Pharm Inc
Priority to AU2001242772A priority Critical patent/AU2001242772A1/en
Publication of WO2001070683A2 publication Critical patent/WO2001070683A2/en
Publication of WO2001070683A3 publication Critical patent/WO2001070683A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

3-Substituted-4-pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof, wherein R1 represents a C¿1?-C18 alkyl group which may be substituted or a C6-C14 aryl group which may be substituted; R?2¿ represents a C¿1?-C18 alkyl group which may be substituted or a C7-C20 aralkyl group which may be substituted; and a medicament comprising said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as neurodegenerative diseases (e.g. Alzheimer disease) and the like.
PCT/JP2001/002344 2000-03-23 2001-03-23 3-substituted-4-pyrimidone derivatives WO2001070683A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001242772A AU2001242772A1 (en) 2000-03-23 2001-03-23 3-substituted-4-pyrimidone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000081937A JP2005289808A (en) 2000-03-23 2000-03-23 3-substituted-4-pyrimidone derivative
JP2000-81937 2000-03-23

Publications (2)

Publication Number Publication Date
WO2001070683A2 WO2001070683A2 (en) 2001-09-27
WO2001070683A3 true WO2001070683A3 (en) 2001-12-06

Family

ID=18598804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002344 WO2001070683A2 (en) 2000-03-23 2001-03-23 3-substituted-4-pyrimidone derivatives

Country Status (3)

Country Link
JP (1) JP2005289808A (en)
AU (1) AU2001242772A1 (en)
WO (1) WO2001070683A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041404A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
US20090062282A1 (en) * 2004-10-15 2009-03-05 Astrazeneca Ab Substituted Amino-Pyrimidones and Uses Thereof
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1997045421A1 (en) * 1996-05-15 1997-12-04 Neurocrine Biosciences, Inc. Oxocoumarin and barbituric acid derivates, their preparation and their use as ligand inhibitors of a corticotropin-releasing factor (crf) and/or a crf-binding protein complex
WO1998024780A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1997045421A1 (en) * 1996-05-15 1997-12-04 Neurocrine Biosciences, Inc. Oxocoumarin and barbituric acid derivates, their preparation and their use as ligand inhibitors of a corticotropin-releasing factor (crf) and/or a crf-binding protein complex
WO1998024780A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives

Also Published As

Publication number Publication date
JP2005289808A (en) 2005-10-20
WO2001070683A2 (en) 2001-09-27
AU2001242772A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
FI950309A (en) Proliiniamidijohdannaisia
EP2261224A3 (en) 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
EP1018514A4 (en) NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
DK0705254T3 (en) Phenyl heterocyclic compounds as cyclooxygenase-2 inhibitors
NO960393L (en) Heterocyclic phenyl compounds as COX-2 inhibitors
ATE255579T1 (en) PYRROLIDINE DERIVATIVES THAT HAVE A PHOSPHOLIPASE A2 INHIBITING EFFECT
NO882036D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE HETEROCYCLIC KETONS.
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
TR200302047T4 (en) Heteroaryl phenyl pyrazole compounds as anti-inflammatory / analgesic agents.
DE69834500D1 (en) XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAINISHEMIA
NO20025035D0 (en) Oxadiazole derivatives that have anticancer effects
WO2001070683A3 (en) 3-substituted-4-pyrimidone derivatives
MX2010002765A (en) 6-pyrimidinyl-pyrimid-2-one derivative.
DE69500673D1 (en) Medicines for the therapeutic and prophylactic treatment of diseases caused by hyperplasia of the smooth muscle cells
DE69931378D1 (en) CHINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF
ATE284684T1 (en) AMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OF THE RETINA
DE60034545D1 (en) USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION
EP0838220A4 (en) Drug for ameliorating brain diseases
HUP0301319A2 (en) Medicines for the prevention and treatment of neurodegenerative diseases containing oxadiazolyl-naphtyridin-2)1h)-one
EP1310498A3 (en) Pyrazoloquinolinone derivatives as protein kinase C inhibitors
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
ES2098070T3 (en) DERIVATIVES OF PIPERIDINE WITH AN ANTIHISTAMINE AND ANTILEUCOTRIENIC ACTIVITY.
WO1999059982A3 (en) Bisoximether derivatives, intermediate products, and their use for combating fungicidal pests and animal pests
ATE319452T1 (en) MEDICINES FOR EATING DISORDERS
DE69007777D1 (en) Derivatives of p-guanidinobenzoic acid for the treatment of cerebrovascular contraction.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP